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Hematopoietic cell transplantation (HCT) is a potential cure for certain hematologic malignancies. However,
because of risks of complications and mortality, this treatment option is limited to patients with minimal
comorbidities. We performed a retrospective cohort study evaluating the impact of pre-HCT systolic
dysfunction on outcomes. We identiﬁed 49 subjects with systolic dysfunction, deﬁned as left ventricular
ejection fraction (LVEF) < 50% and 49 controls (matched by age, gender, conditioning regimen, and HCT donor
number; all with LVEF  50%) undergoing HCT at the University of Minnesota between 2002 and 2012.
Treatment complications, use of beta-blockers and angiotensin-converting enzyme inhibitors, and overall
survival (OS) after HCT out to 24 months were analyzed. The median LVEF was 45% (range, 27.5% to 49%) for
the study group and 60% (range, 50% to 69%) for controls. The majority of patients in both groups (81.6%)
received reduced-intensity conditioning (RIC). Treatment-related mortality (TRM) at day 100 was identical,
with a cumulative incidence of 14% in the study (95% conﬁdence interval [CI], 5% to 24%) versus 14% in
controls (95% CI, 5% to 24%) (P ¼ .89). Two-year OS was similar in the study group (53%; 95% CI, 38% to 66%)
versus controls (61%; 95% CI, 46% to 73%) (P ¼ .34). LVEF  43% was associated with improved OS at 1 year
(hazard ratio [HR], .36; 95% CI, .15 to .87; P ¼ .02). There was no signiﬁcant difference in the incidence of non
elife-threatening cardiac complications (12.2% in cases versus 8.2% in controls, P ¼ .50) or serious (life-
threatening or fatal) cardiac complications (4.1% in cases versus 2.0% in controls, P ¼ .56). Pre-existing cor-
onary artery disease was associated with increased TRM at 100 days (HR, 4.35; 95% CI, 1.24 to 15.32; P ¼ .02).
Cardiac medication use had no effect on TRM. Our study demonstrates that patients with asymptomatic
borderline systolic dysfunction can safely undergo HCT with RIC. Coronary artery disease remains a risk factor
for increased TRM. Patients with borderline systolic dysfunction can safely undergo HCT, but may need
particular vigilance for potential hemodynamic or ischemic cardiac complications.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HCT)
is a potential cure for various hematologic malignancies.
Given the risk of treatment-related complications and mor-
tality, this treatment is only offered to patients considered
able to tolerate treatment toxicity. Reduced-intensity con-
ditioning (RIC) regimens have expanded the patient popu-
lation being offered HCT to include older patients [1-3]. This
older population often presents with added comorbidities,
which may require speciﬁc attention and management. Theedgments on page 303.
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ty for Blood and Marrow Transplantation.HCT-speciﬁc comorbidity index is a validated tool to help
predict transplantation risk based on the presence of various
comorbidities [4]. According to this model, a cardiac co-
morbidity (coronary artery disease [CAD], congestive heart
failure [CHF], myocardial infarction [MI], or ejection fraction
 50%) is considered low risk. However, with few studies
supporting this data, there remains concern about trans-
plantation outcomes in patients with cardiomyopathy.
Additionally, the signiﬁcance of these individual cardiac
comorbidities is uncertain. The relative infrequency of major
cardiac complications attributable to HCT, occurring in < 1%
of transplantations at our institution, suggests that patients
with impaired cardiac function are not predisposed to worse
transplantation outcomes [5]. Qazilbash et al. showed that
patients with reduced left ventricular ejection fraction (LVEF)
can safely undergo allogeneic HCT [6]. We investigated
Table 1
Patient Comorbidities and Medication Use
Case (n ¼ 49) Control (n ¼ 49) P Value
Median LVEF 45.0% (27.5%-49.0%) 60.0% (50.0%-69.0%) <.01
Anthracycline dose,
median (mg/m2)
220.0 (.0-800.0) 216.0 (.0-580.0) .24
CAD 6 (12.2%) 1 (2.0%) .05
Arrhythmia 3 (6.1%) 0 .08
CHF 5 (10.2%) 1 (2.0%) .09
Diabetes mellitus 8 (16.3%) 3 (6.1%) .11
COPD 1 (2.0%) 0 .31
CKD 7 (14.3%) 3 (6.1%) .19
Hypertension 9 (18.4%) 7 (14.3%) .58
Dyslipidemia 8 (16.3%) 5 (10.2%) .37
Prior MI 3 (6.1%) 0 .08
ACE inhibitor 15 (30.6%) 3 (6.1%) <.01
ARB 3 (6.1%) 1 (2.0%) .31
Beta blocker 16 (32.7%) 2 (4.1%) <.01
Aspirin 6 (12.2%) 0 .01
Clopidogrel 2 (4.1%) 0 .15
Statin 9 (18.4%) 2 (4.1%) .03
Loop diuretic 4 (8.2%) 1 (2.0%) .17
COPD indicates chronic obstructive pulmonary disease; CKD, chronic kidney
disease; ARB, angiotensin receptor blocker.
Data presented are n (%) unless otherwise indicated.
Table 2
Patient Characteristics
Characteristic Case (n ¼ 49) Control (n ¼ 49)
Male 31 (63.3%) 31 (63.3%)
Female 18 (36.7%) 18 (36.7%)
Age, median (range), yr 52.3 (19.1-69.2) 54.3 (20.7-72.5)
Transplantation indication
ALL 3 (6.1%) 3 (6.1%)
AML 22 (44.9%) 22 (44.9%)
Other leukemia 3 (6.1%) 3 (6.1%)
Myelodysplasia 3 (6.1%) 3 (6.1%)
Non-Hodgkin lymphoma 14 (28.6%) 14 (28.6%)
Hodgkin lymphoma 3 (6.1%) 3 (6.1%)
Myeloproliferative disease 1 (2.0%) 1 (2.0%)
Conditioning
Myeloablative conditioning 9 (18.4%) 9 (18.4%)
RIC 40 (81.6%) 40 (81.6%)
Stem cell source
Bone marrow 2 (4%) 1 (2%)
PBSC 19 (39%) 16 (33%)
UCB 28 (57%) 32 (65%)
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia;
PBSC, peripheral blood stem cells; UCB, umbilical cord blood.
Data presented are n (%) unless otherwise indicated.
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tolerate transplantation. We report the outcomes of
consecutive patients undergoing HCT with a reduced LVEF.
MATERIALS AND METHODS
Patient Selection
We performed a retrospective cohort study comparing the HCT
outcomes of subjects with systolic dysfunction compared with controls who
had normal systolic function. The University of Minnesota HCT database
contains prospectively collected data on all patients who underwent
transplantation at our institution. All adult patients (18 years or older)
undergoing allogeneic HCT from January 1, 2002 to December 31, 2012 with
a history of cardiovascular disease were identiﬁed. The initial screen yielded
117 subjects. Pretransplantation cardiac evaluation by either echocardio-
gram ormultiple gated acquisition scan identiﬁed 49 of these 117 subjects as
having an LVEF < 50% before transplantation.
The control group comprised 49 randomly selected subjects who
received transplants between 2002 and 2012. Control subjects were
identiﬁed using HCT database at University of Minnesota, matching the
study group by age (5 years), gender, diagnosis, conditioning regimen
(myeloablative versus reduced intensity), and number of stem cell units
transplanted (single versus double).
Patient Characteristics
We reviewed available records for cardiovascular risk factors before
transplantation, including tobacco use, CAD, cardiac arrhythmia, CHF,
MI, hypertension, dyslipidemia, diabetes mellitus, chronic obstructive
pulmonary disease, and chronic kidney disease (glomerular ﬁltration
rate < 60 mL/minute). Additionally, we documented use of the following
cardiac medications before HCT: angiotensin-converting enzyme in-
hibitors (ACE inhibitors), angiotensin receptor blockers, beta blockers,
aspirin, clopidogrel, statins, and loop diuretics. We collected data on the
subjects’ anthracycline exposure before transplantation or estimated it
based on cycles of treatment with an anthracycline. A doxorubicin
equivalent dose for other antitumor antibiotics (daunorubicin, idar-
ubicin, and mitoxantrone) was calculated (1 mg doxorubicin ¼ 3 mg
idarubicin ¼ 2.8 mg mitoxantrone ¼ .67 mg daunorubicin) based on
previously reported maximum cumulative doses associated with car-
diotoxicity [7-10].
Endpoints
The primary endpoint was 100 day transplantation-related morality
(TRM) in the study and control groups. Secondary endpoints included TRM
at 1 year and 2 years, overall survival (OS) at 1 year out to 2 years, and
occurrence of cardiac complications (minor and serious) at any time after
HCT. Cardiac events were identiﬁed by database and medical record review
and were categorized by the Common Terminology Criteria for Adverse
Events version 4.0 [11]. We subdivided events into minor (grades 1 to 3)
and serious events (grades 4 and 5). In an attempt to accurately identify
cardiac complications attributable to HCT, we excluded 7 cardiac events as
review of the record identiﬁed a noncardiac cause as the underlying
etiology (sepsis, n ¼ 5; veno-occlusive disease, n ¼ 1; and multiorgan
failure, n ¼ 1).
Statistical Analysis
Data on pretransplantation patient characteristics, transplantation
complications, and outcomes were prospectively collected by the biosta-
tistical support group at the University of Minnesota, using standardized
collection procedures.
Comparison of patient and transplantation characteristics between
study and control group were performed using chi-square or Wilcoxon’s
rank sum test, as appropriate. TRM and OS were the outcome variables
studied. The Kaplan-Meier method was used to estimate OS, whereas cu-
mulative incidence was estimated for the risk of TRM, with malignant
relapse as the competing hazard. Cox regression models were conducted for
OS and competing risk regression was employed for TRM [12,13]. We also
investigated a threshold LVEF associated with different transplantation
outcomes. We tested distribution of pre-HCT LVEF versus day 100 OS and
found that the lowest 10th percentile of LVEF (corresponding to LVEF of 43%)
was the optimal cut-off point. LVEF < 43% and  43% was the primary factor
considered for each endpoint. Other covariates, including group (case versus
control), medication, and comorbidity risk factors (listed in Table 1), were
also compared for each endpoint. Multivariate analysis was not done
because the factors showing signiﬁcance in univariate analysis were highly
correlated to each other.
All P values were 2 sided. Analyses were performed using SAS 9.3
software (Cary, NC).RESULTS
Patient Demographics
Patient characteristics were similar between study and
control group (Table 2). The median age at time of trans-
plantation was 52.3 (range, 19.1 to 69.2) years for the study
group and 54.3 (range, 20.7 to 72.5) for the control group
(P ¼ .89). The majority of subjects in both groups were male
and received RIC. Acute myeloid leukemia was the most
common indication for transplantation. Nearly all subjects
received conditioning with cyclophosphamide (n ¼ 47 [96%]
cases; n ¼ 48 [98%] controls) and total body irradiation
(n ¼ 47 [96%] cases; n ¼ 46 [94%] controls). The hemato-
poietic stem cell source was from a single donor (umbilical
cord blood, peripheral blood stem cells, or bone marrow) for
25 subjects (51%) in each group, whereas the remaining 24
subjects (49%) in each group received double umbilical cord
blood (P ¼ 1.00). The median LVEF was 45% (range, 27.5% to
49%) for the study group, compared with 60% (range, 50% to
69%) for the control group (P < .01) (Figure 1).
Table 3
Survival Outcomes and Proportion of Complications
Outcome Case
(n ¼ 49)
Control
(n ¼ 49)
P Value
TRM at day 100 7 (14.3%) 7 (14.3%) 1.00
TRM at 1 year 8 (17%) 8 (17%) .87
TRM at 2 years 9 (19%) 9 (19%) .88
OS at day 100 37 (75.5%) 42 (85.7%) .20
OS at 1 year 28 (57.1%) 34 (69.4%) .21
OS at 2 years 25 (51.0%) 29 (59.2%) .42
Minor cardiac complication 6 (12.2%) 4 (8.2%) .50
Serious cardiac complication 2 (4.1%) 1 (2.0%) .56
Hemodialysis initiation by day 100 3 (6.1%) 3 (6.1%) 1.00
Mechanical ventilation by day 100 11 (22.4%) 8 (16.3%) .44
Figure 2. TRM was identical between the study and control groups at 100
days.
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trol groups (Table 1) with no signiﬁcant difference in a his-
tory of the following: tobacco use, arrhythmia, CHF, diabetes
mellitus, chronic obstructive pulmonary disease, hyperten-
sion, dyslipidemia, or MI. However, subjects in the study
group were more likely to have a diagnosis of CAD compared
with patients in the control group (n¼ 6 [12.2%] versus n¼ 1
[2%], P ¼ .05). The number of patients exposed to  400 mg/
m2 of anthracycline before transplantation was similar (n ¼
10 [20.4%] versus n¼ 4 [8.2%], P¼ .35) between the study and
control groups, respectively. Five subjects in the study group
and 1 subject in the control group (diastolic dysfunction) had
a history of symptomatic CHF.
At the time of transplantation, subjects in the study group
were more likely to be on beta blockers (n ¼ 16 [32%] versus
n ¼ 2 [4.1%], P < .01), ACE inhibitors (n ¼ 15 [30.6%] versus
n¼ 3 [6.1%]; P< .01), aspirin (n¼ 6 [12.2%] versus n¼ 0 [0%],
P¼ .01), and statins (n¼ 9 [18.4%] versus n¼ 2 [4.1%], P¼ .03)
compared with subjects in the control group (Table 1). There
was no difference in the use of angiotensin receptor blockers
(n ¼ 3 [6.1%] versus n ¼ 1 [2%], P ¼ .31), clopidogrel (n ¼ 2
[4.1%] versus n ¼ 0 [0%], P ¼ .15), or loop diuretics (n ¼ 4
[8.2%] versus n ¼ 1 [2%], P ¼ .17) between the study and
control groups, respectively.Figure 1. Box plot comparing the range of ejection fractions of the 2
groups.TRM and OS
TRM and OS are reported in Table 3 and in Figures 2 and 3.
There was no difference in the 100-day TRM. There were 7
transplantation-related deaths for a cumulative incidence of
14%, (95% conﬁdence interval [CI], 5% to 24%) in the study
group and 7 transplantation-related deaths for a cumulative
incidence of 14% (95% CI, 5% to 24%) in the controls (P ¼ .89).
TRM was identical between the study and control at 1 year
(n¼ 8 [16%]; 95% CI, 6% to 27% for both groups; P¼ .87) and 2
years (n¼ 9 [19%]; 95% CI, 8% to 30% for both groups; P¼ .88).
Additionally, there was no difference in OS at 100 days (n ¼
37 [76%]; 95% CI, 61% to 85% versus n ¼ 42 [86%]; 95% CI, 72%
to 93%; P ¼ .24), at 1 year (n ¼ 29 [59%]; 95% CI, 44% to 71%
versus n¼ 35 [71%]; 95% CI, 57% to 82%; P¼ .20), or at 2 years
(n¼ 26 [53%]; 95% CI, 38% to 66% versus n¼ 30 [61%]; 95% CI,
46% to 73%; P ¼ .30) between the study and control groups,
respectively.
CAD was the only comorbidity that was associated with a
signiﬁcantly increased risk of TRM at 100 days (hazard ratio
[HR], 4.35; 95% CI, 1.24 to 15.32; P¼ .02) and 1 year (HR, 3.77;
95% CI, 1.06 to 13.43; P ¼ .04). Other comorbidities or use of
cardiac medications were not associated with differences in
TRM (Table 4).
Subjects with an LVEF < 43%, in the lowest 10th
percentile, had signiﬁcantly lower OS at 1 year compared
to the remainder of the cohort (HR, 2.79; 95% CI, 1.15
to 6.78; P ¼ .02). The 1-year survival was only 33% (95% CI,
8% to 62%) versus 69% (95% CI, 58% to 77%) for the others
(P ¼ .02).Figure 3. Kaplan-Meier curves show similar survival between the study and
control groups.
Table 4
Comorbidity and Medication Hazard Ratios
Parameter HR (95% CI) P Value
CAD 4.35 (1.24-15.32) .02
Hypertension .84 (.19-3.67) .81
CHF 1.27 (.15-10.59) .83
Dyslipidemia 3.04 (.95-9.74) .06
Prior MI 2.68 (.38-18.75) .32
High prior anthracycline (>300 mg/m2) .14 (.02-1.05) .06
ACE inhibitor 1.87 (.59-5.86) .29
Beta blocker 1.24 (.35-4.39) .74
Aspirin 3.08 (.66-14.37) .15
Statin 2.55 (.68-9.53) .17
Clopidogrel 4.46 (.69-28.95) .12
Day 100 TRM univariate regression.
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Overall, there were few cardiac complications in both the
study group and the controls. There was no signiﬁcant dif-
ference in the total number of minor (n ¼ 6 [12.2%] versus
n ¼ 4 [8.2%], P ¼ .50] or serious cardiac complications (n ¼ 2
[4.1%] versus n ¼ 1 [2%], P ¼ .56) between the study and
control groups, respectively (Table 3). The minor complica-
tions in the study group were CHF exacerbation (n ¼ 4) and
atrial ﬁbrillation (n ¼ 3); 1 subject had both. Two in the
control group had CHF exacerbations, 1 had atrial ﬁbrillation,
and 1 had an MI. The serious (life-threatening or fatal)
complications in the study group were CHF exacerbation
requiring mechanical ventilation (n ¼ 1) and idiopathic car-
diac tamponade requiring an emergent pericardial window
procedure (n ¼ 1). There were no deaths in the study group
attributed to a cardiac complication. There was 1 fatal MI in
the control group.
DISCUSSION
Our ﬁndings illustrate that asymptomatic patients with
borderline systolic dysfunction can undergo HCT without
increased risk of mortality or complication. However, patients
with an LVEF < 43% had signiﬁcantly worse outcomes. This
suggest that LVEF < 43% could be considered an important
risk factor in candidates for HCTand requires further study for
validation. Subjects with a history of CAD were at increased
risk for TRM, but we found no association between the use of
speciﬁc cardiac medications and outcome.
As the HCT population ages, better understanding of
management of patient comorbidities during trans-
plantation is needed. Prior studies on the signiﬁcance of a
reduced LVEF in patients undergoing HCT are conﬂicting,
with 4 reports that suggesting a reduced LVEF is a risk for
serious cardiac complication [6,7,14-19]. We focused on the
association of impaired LVEF and TRM. Our data are consis-
tent with the ﬁndings of Qazilbash et al. that patients with
impaired LVEF can safely undergo transplantation without
increased risk of TRM or cardiac complication. Their study
noted an increase in cardiac complications in patients with 1
of the following risk factors: history of tobacco use, hyper-
tension, hyperlipidemia, CAD, arrhythmia, prior MI, and CHF.
We investigated whether the presence of these risk factors
placed patients at increased risk of TRM and found that only
a history of CAD was a risk factor for increased TRM at day
100 and 1 year.We did not ﬁnd any risk factors that increased
the risk of cardiac complications.
There is little speciﬁc data on how to manage systolic
dysfunction in patients undergoing HCT; thus, its manage-
ment during transplantation should be the same as thegeneral populationwith beta blockers and ACE inhibitors per
the American Heart Association and American College of
Cardiology guidelines [20]. Evidence that beta blockers
(particularly carvedilol) and ACE inhibitors are effective for
preventing anthracycline-induced cardiomyopathy provides
further rational for this practice in oncology patients [21-24].
Furthermore, these medications have been shown to
improve LVEF in subjects with anthracycline-induced car-
diomyopathy [25]. Our data did not show any association
with cardiac medication use and TRM, but since cardiac
complications were rare, we could not identify any best
practices in our cohorts.Limitations
The small number of subjects in our study group and
infrequent cardiac events limit the power for conclusions
from our study. Because most of the subjects in our study
group had minimally reduced LVEF, we are unable to make
conclusions about HCT outcomes in patients with more
severely depressed LVEF. Also, the majority of subjects in our
study group did not have symptomatic CHF, so our results
apply to those without symptomatic systolic dysfunction.
Because of several variables, including age and possibly
decreased LVEF, the majority of subjects in our study group
underwent RIC. Additionally, a potential for selection bias of
the study group exist as it is possible that patients with se-
vere or symptomatic heart failure may not have been
referred for transplantation. At our institution, though, few
patients have been denied transplantation based only on
depressed LVEF without symptomatic CHF. Our practice for
patients with signiﬁcant cardiac comorbidity is to obtain a
consultation from a cardiologist with expertise in cardio-
oncology to optimize the patient’s cardiac status and
closely manage patients during the transplantation process.Clinical Signiﬁcance of Findings
Evaluation of cardiac systolic function by multiple gated
acquisition scan, echocardiogram, or cardiac magnetic reso-
nance imaging is usually part of a pretransplantation evalu-
ation. Our results help clinicians interpret the signiﬁcance of
depressed LVEF in HCT candidates. We suggest that patients
with minimally depressed LVEF (>43%) remain candidates
for transplantation with RIC and are not at particularly
higher risk for mortality or complications. Lower LVEF or a
history of CAD were risk factors in our study, and such pa-
tients need extra attention during the pretransplantation
evaluation and throughout their course.ACKNOWLEDGMENTS
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